TOMI's SteraMist Service Revenue Surges Past Prior Years
Event summary
- TOMI's SteraMist iHP Service and Support revenue hit $1.7M YTD, surpassing full-year totals from 2024 and 2025 ($1.3M each).
- Key contracts include repeat engagements with Integra Pharma, Catalent, Cleveland Clinic, and LFB USA.
- Recurring on-site support averages 4 visits monthly at facilities like the CDC and other government/commercial accounts.
- Service revenue growth reflects increasing demand for contracted decontamination services with quick turnaround.
The big picture
TOMI's accelerating service revenue highlights the growing importance of recurring revenue models in the decontamination sector. The company's ability to secure repeat contracts with major healthcare and government institutions positions it favorably in an industry increasingly focused on infection prevention. This shift toward service-based revenue could enhance TOMI's financial stability amid broader market volatility.
What we're watching
- Recurring Revenue Mix
- How TOMI will balance service revenue growth against system sales in its broader diversification strategy.
- Customer Retention
- Whether TOMI can sustain its contracted service relationships with high-profile clients like Cleveland Clinic and the CDC.
- Global Expansion
- The pace at which TOMI can scale its service operations internationally beyond North America.